Trials / Recruiting
RecruitingNCT03374267
Registry Platform Urologic Cancer
Clinical Research Platform On Urologic Cancer Treatment And Outcome (Registry Platform Urologic Cancer; CARAT)
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,930 (estimated)
- Sponsor
- iOMEDICO AG · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with advanced renal cell carcinoma or urothelial cancer in Germany.
Detailed description
CARAT is a national, observational, prospective, longitudinal, multicenter cohort study (tumor registry platform) with the purpose to record information on the antineoplastic treatment of renal cell carcinoma and urothelial cancer in Germany. The registry will follow patients with advanced renal carcinoma for up to three years, and patients with advanced urothelial cancer for up to two years. It will identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented. Moreover, data on perioperative therapies in patients with high-risk muscle-invasive urothelial carcinoma and radical surgery will be collected. Health-related quality of life (HRQoL) in patients with advanced renal cell carcinoma or advanced urothelial cancel will be evaluated for up to two years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Routine care as per site standard. | Physician's choice according to patient's needs. |
Timeline
- Start date
- 2017-12-07
- Primary completion
- 2028-09-01
- Completion
- 2028-09-01
- First posted
- 2017-12-15
- Last updated
- 2025-09-22
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT03374267. Inclusion in this directory is not an endorsement.